GlaxoSmithKline PE Ratio 2006-2018 | GSK

Current and historical p/e ratio for GlaxoSmithKline (GSK) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. GlaxoSmithKline PE ratio as of October 22, 2018 is 13.41.
GlaxoSmithKline PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-10-22 40.50 44.51
2018-06-30 39.82 $0.91 43.76
2018-03-31 38.12 $0.57 66.87
2017-12-31 34.00 $0.79 43.04
2017-09-30 38.36 $1.22 31.45
2017-06-30 40.24 $1.00 40.24
2017-03-31 38.89 $0.83 46.85
2016-12-31 35.03 $0.47 74.54
2016-09-30 38.78 $0.12 323.19
2016-06-30 38.56 $0.03 1285.47
2016-03-31 35.66 $0.38 93.84
2015-12-31 34.41 $5.25 6.55
2015-09-30 32.36 $6.11 5.30
2015-06-30 34.60 $6.04 5.73
2015-03-31 37.84 $6.41 5.90
2014-12-31 34.53 $1.83 18.87
2014-09-30 36.65 $2.83 12.95
2014-06-30 42.06 $3.20 13.14
2014-03-31 41.54 $3.39 12.25
2013-12-31 40.96 $3.54 11.57
2013-09-30 38.04 $2.47 15.40
2013-06-30 37.48 $2.56 14.64
2013-03-31 34.81 $2.70 12.89
2012-12-31 31.78 $2.94 10.81
2012-09-30 33.34 $3.15 10.58
2012-06-30 32.49 $3.28 9.91
2012-03-31 31.64 $3.19 9.92
2011-12-31 31.56 $3.29 9.59
2011-09-30 28.21 $2.08 13.56
2011-06-30 28.96 $2.00 14.48
2011-03-31 25.62 $1.12 22.87
2010-12-31 25.75 $0.97 26.54
2010-09-30 25.61 $2.44 10.50
2010-06-30 21.76 $2.52 8.64
2010-03-31 24.34 $3.63 6.70
2009-12-31 26.29 $3.47 7.58
2009-09-30 24.29 $3.02 8.04
2009-06-30 21.47 $3.10 6.93
2009-03-31 18.63 $3.15 5.91
2008-12-31 22.04 $3.45 6.39
2008-09-30 25.38 $3.25 7.81
2008-06-30 25.53 $3.27 7.81
2008-03-31 24.22 $3.24 7.47
2007-12-31 28.35 $3.36 8.44
2007-09-30 29.63 $3.37 8.79
2007-06-30 28.89 $3.33 8.67
2007-03-31 30.23 $3.23 9.36
2006-12-31 28.59 $3.10 9.22
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $100.437B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $372.065B 17.44
Pfizer (PFE) United States $264.129B 15.46
Novartis AG (NVS) Switzerland $201.850B 17.25
Merck (MRK) United States $195.663B 17.28
AbbVie (ABBV) United States $127.608B 12.47
Eli Lilly (LLY) United States $120.319B 22.27
Sanofi (SNY) France $111.710B 14.14
Novo Nordisk (NVO) Denmark $105.365B 16.84
AstraZeneca (AZN) United Kingdom $100.024B 11.00
Bristol-Myers Squibb (BMY) United States $83.165B 15.05